|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
|
|
2
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Bono JS and Rowinsky EK: The ErbB
receptor family: a therapeutic target for cancer. Trends Mol Med.
8(Suppl 4): S19–S26. 2002.PubMed/NCBI
|
|
4
|
Woodburn JR: The epidermal growth factor
receptor and its inhibition in cancer therapy. Pharmacol Ther.
82:241–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gadducci A, Cosio S and Genazzani AR: Old
and new perspectives in the pharmacological treatment of advanced
or recurrent endometrial cancer: hormonal therapy, chemotherapy and
molecularly targeted therapies. Crit Rev Oncol Hematol. 58:242–256.
2006. View Article : Google Scholar
|
|
6
|
Nakagawa K, Tamura T, Negoro S, et al:
Phase I pharmacokinetic trial of the selective oral epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib
(‘Iressa’, ZD1839) in Japanese patients with solid malignant
tumors. Ann Oncol. 14:922–930. 2003.
|
|
7
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer. J Clin Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Natale R, Skarin A, Maddox A, et al:
Improvement in symptoms and quality of life for advanced
non-small-cell lung cancer patients receiving ZD1839 (‘Iressa’) in
IDEAL 2. Proc Am Soc Clin Oncol. 21:292a2002.
|
|
9
|
Rivera F, Vega-Villegas ME and López-Brea
MF: Cetuximab, its clinical use and future perspectives. Anticancer
Drugs. 19:99–113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pirker R, Pereira JR, Szczesna A, et al:
Cetuximab plus chemotherapy in patients with advanced
non-small-cell lung cancer (FLEX): an open-label randomised phase
III trial. Lancet. 373:1525–1531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy of gefitinib, an inhibitor of the epidermal growth factor
receptor tyrosine kinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Franceschi E, Cavallo G, Lonardi S, et al:
Gefitinib in patients with progressive high-grade gliomas: a
multicentre phase II study by Gruppo Italiano Cooperativo di
Neuro-Oncologia (GICNO). Br J Cancer. 96:1047–1051. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salzberg M, Rochlitz C, Morant R, et al:
An open-label, noncomparative phase II trial to evaluate the
efficacy and safety of docetaxel in combination with gefitinib in
patients with hormone-refractory metastatic prostate cancer.
Onkologie. 30:355–360. 2007. View Article : Google Scholar
|
|
14
|
Small EJ, Fontana J, Tannir N, et al: A
phase II trial of gefitinib in patients with non-metastatic
hormone-refractory prostate cancer. BJU Int. 100:765–769. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goncalves A, Fabbro M, Lhommé C, et al: A
phase II trial to evaluate gefitinib as second- or third-line
treatment in patients with recurring locoregionally advanced or
metastatic cervical cancer. Gynecol Oncol. 108:42–46. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giaccone G, González-Larriba J, Van
Oosterom A, et al: Combination therapy with gefitinib, an epidermal
growth factor receptor tyrosine kinase inhibitor, gemcitabine and
cisplatin in patients with advanced solid tumors. Ann Oncol.
15:831–838. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giaccone G, Herbst RS, Manegold C, et al:
Gefitinib in combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin
Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Breathnach OS, Freidlin B, Conley B, et
al: Twenty-two years of phase III trials for patients with advanced
non-small-cell lung cancer: sobering results. J Clin Oncol.
19:1734–1742. 2001.PubMed/NCBI
|
|
19
|
McKillop D, Partridge EA, Hutchison M, et
al: Pharmacokinetics of gefitinib, an epidermal growth factor
receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica.
34:901–915. 2004. View Article : Google Scholar
|
|
20
|
Herbst RS, Giaccone G, Schiller JH, et al:
Gefitinib in combination with paclitaxel and carboplatin in
advanced non-small-cell lung cancer: a phase III trial - INTACT 2.
J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ciardiello F, Caputo R, Bianco R, et al:
Antitumor effect and potentiation of cytotoxic drugs activity in
human cancer cells by ZD-1839 (Iressa), an epidermal growth factor
receptor-selective tyrosine kinase inhibitor. Clin Cancer Res.
6:2053–2063. 2000.
|
|
22
|
Sirotnak FM, Zakowski MF, Miller VA, Scher
HI and Kris MG: Efficacy of cytotoxic agents against human tumor
xenografts is markedly enhanced by coadministration of ZD1839
(Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res.
6:4885–4892. 2000.PubMed/NCBI
|
|
23
|
Ohtsuka K, Ohnishi H, Morii T, et al:
Downregulated ABCG2 enhances sensitivity to topoisomerase I
inhibitor in epidermal growth factor receptor tyrosine kinase
inhibitor-resistant non-small cell lung cancer. J Thorac Oncol.
5:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cohen MH, Williams GA, Sridhara R, Chen G
and Pazdur R: FDA drug approval summary: gefitinib (ZD1839)
(Iressa®) tablets. Oncologist. 8:303–306. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miller VA, Kris MG, Shah N, et al:
Bronchioloalveolar pathologic subtype and smoking history predict
sensitivity to gefitinib in advanced non-small-cell lung cancer. J
Clin Oncol. 22:1103–1109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shukla S, Skoumbourdis AP, Walsh MJ, et
al: Synthesis and characterization of a BODIPY conjugate of the
BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for
transport of Tasigna and its fluorescent derivative by ABC drug
transporters. Mol Pharm. 8:1292–1302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McKillop D, McCormick A, Miles GS, et al:
In vitro metabolism of gefitinib in human liver microsomes.
Xenobiotica. 34:983–1000. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Osherov N and Levitzki A:
Epidermal-growth-factor-dependent activation of the src-family
kinases. Eur J Biochem. 225:1047–1053. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pollak M, Beamer W and Zhang JC:
Insulin-like growth factors and prostate cancer. Cancer Metastasis
Rev. 17:383–390. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sachdev D and Yee D: The IGF system and
breast cancer. Endocr Relat Cancer. 8:197–209. 2001. View Article : Google Scholar
|
|
31
|
Pollak MN, Schernhammer ES and Hankinson
SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer.
4:505–518. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baserga R: Targeting the IGF-1 receptor:
from rags to riches. Eur J Cancer. 40:2013–2015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Frattali A and Pessin J: Relationship
between α subunit ligand occupancy and β subunit
autophosphorylation in insulin/insulin-like growth factor-1 hybrid
receptors. J Biol Chem. 268:7393–7400. 1993.
|
